Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.

Cancer science - 1 Dec 2023

Fukada Ippei, Mori Seiichi, Hayashi Naomi, Hosonaga Mari, Xiaofei Wang, Yamazaki Masumi, Ueki Arisa, Kiyotani Kazuma, Tonooka Akiko, Takeuchi Kengo, Ueno Takayuki, Takahashi Shunji

Abstract excerpt

Cancer genomic profile (CGP) testing, which is covered by the national health insurance system in Japan, has been introduced as a routine clinical practice. However, the effects of CGP testing on prognoses remain unclear. Drug accessibility rates and prognoses after CGP testing were retrospectively investigated in 713 patients who underwent CGP testing examined by our molecular tumor board between November 2019...

Topics

Join the communities discussing this publication.

Genomics
Mutation
Neoplasms
Neoplasms, Second Primary
Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 37858313
DOI: 10.1111/cas.15993
PMCID: PMC10728004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.PMID 37858313Read ↗

Assessment of a cancer genomic profile test for patients with metastatic breast cancer.Semantic proximity Read ↗

Initial assessment of a cancer genomic profile test for patients with metastatic breast cancer: a retrospective studySemantic proximity Read ↗

Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in JapanSemantic proximity Read ↗

Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Semantic proximity Read ↗

Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, JapanSemantic proximity Read ↗

Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution.Semantic proximity Read ↗

A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.Semantic proximity Read ↗

Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancerSemantic proximity Read ↗

Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers.Semantic proximity Read ↗

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.Semantic proximity Read ↗

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.Semantic proximity Read ↗

A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.